Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-043120

Chief Accounting Officer sold 684 shares at an average $3.45 ($2,363)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hagen Brett R · Chief Accounting Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-07-19 Sale : show line 1 in the form 10b5-1 −342 $3.56 $1,218 129,170 D
2023-07-20 Sale : show line 2 in the form 10b5-1 −342 $3.35 $1,145 128,828 D
Open-market sales · 684 sh · avg $3.45 · $2,363
Loading xslF345X05/doc4.xml…